Cimicoxib

DB05095InvestigationalSmall molecule

Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia. If approved, Cimicoxib would be the first drug in decades to treat depression...

Mechanism: Depression and schizophrenia are inflammatory diseases. Increased levels of pro-inflammatory cytokines and prostaglandin E (PGE) have repeatedly been described in major depression. COX-2 inhibitors inhibit production of both. Cimicoxib is a selective COX-2 inhibitor. The mechanism by which some COX-2 inhibitors work in depression could be linked to their anti-inflammatory mechanisms.
Curator reviewed
Primary indication: Investigated for use/treatment in depression.Curator reviewed
Formula / weight: C₁₆H₁₃ClFN₃O₃S · 381.809 g/mol (avg)

Resolves to

Compound

UNIIW7FHJ107MCCAS265114-23-6ChEMBLCHEMBL435381ChEBI76127PubChem213053

Structure

InChIKeyKYXDNECMRLFQMZ-UHFFFAOYSA-NSMILESCOC1=C(F)C=C(C=C1)C1=C(Cl)N=CN1C1=CC=C(C=C1)S(N)(=O)=O

Targets

P35354PTGS2

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,410Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

3Marketed productsAcross 1 country and 1 labeller

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cimicoxib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account